Lumbrokinase
An earthworm fibrinolytic with a thinner file than nattokinase and the same class caution.
D+
Evidence grade
D
Worth it
$25-45/month
Typical cost
DoseProducts provide 20 to 40 mg of lumbrokinase extract per day, standardized in activity units (commonly 600,000 to 720,000 IU per capsule), taken away from food. Potency expression varies by brand and no pharmacopeial standard governs the US market, so the number on the label is softer than it looks.
BasisLumbrokinase sells cardiovascular protection on enzyme activity plus small unreplicated trials, at a premium price, with a bleeding-relevant mechanism.
Lumbrokinase is a group of fibrin-digesting enzymes extracted from earthworms (Lumbricus rubellus), sold for circulation and clot prevention. We grade Lumbrokinase D+ on evidence and D for worth-it at about $25-45 per month.
What it does
Lumbrokinase is a group of fibrin-digesting enzymes extracted from earthworms (Lumbricus rubellus), sold for circulation and clot prevention. It completes this extension's enzyme pair and belongs to the fibrinolytic supplement cluster this library tracks for interaction purposes.
What the research says
Fibrinolytic activity is demonstrable; clinical outcome evidence is small, regional, and unconfirmed
Evidence: weak. Lumbrokinase enzymes digest fibrin in vitro and in animal models. Human work consists of small Chinese studies, including a trial in stable angina reporting fewer events on lumbrokinase added to standard care, none independently replicated or run at the scale its claims (clot prevention, stroke protection) would require. The pattern matches its cousin nattokinase (graded C- in this library on a larger file that includes a large null trial): plausible enzyme, thin outcomes.
Lumbrokinase sells cardiovascular protection on enzyme activity plus small unreplicated trials, at a premium price, with a bleeding-relevant mechanism. That combination is the fibrinolytic category's signature, and this record grades it at the category's floor until a trial at scale exists. D+, with the safety notes carrying the weight they carried for nattokinase.
Is it worth it?
Evidence (D+) sits far below the leaderboard floor, so the worth-it grade is capped at C+; the derived value lands at D, because roughly $35 a month buys the thinnest file in the fibrinolytic cluster. Derived from the October 2026 worth-it model.
Typical cost
$25-45/month
Common form, not a brand recommendation
Dosage context established
Products provide 20 to 40 mg of lumbrokinase extract per day, standardized in activity units (commonly 600,000 to 720,000 IU per capsule), taken away from food. Potency expression varies by brand and no pharmacopeial standard governs the US market, so the number on the label is softer than it looks.
Worth-it leaderboard
Lumbrokinase sits outside the worth-it top 20.
Lumbrokinase sits outside the current top 20 on the gated leaderboard. The leaders below clear an evidence floor of B- before price counts at all, so cheap alone never earns a rank.
- 1AWorth itCreatine evidence A-~$5-10/mo
- 2AWorth itCaffeine evidence B+~$5-10/mo
- 3AWorth itVitamin D evidence B~$5-8/mo
See the full worth-it leaderboard →
When the evidence moves a grade, this ranking moves with it. Thursday is where you hear it first.
Safety notes
Treat as an anticoagulant-adjacent product: bleeding risk rises alongside aspirin, anticoagulants, and other fibrinolytic or antiplatelet supplements (this library's aged garlic, raw garlic, and nattokinase records carry the same flag); stop before surgery and disclose it to the surgical team. Anyone who has had a hemorrhagic stroke should not use fibrinolytic supplements without specialist direction. These cautions are precautionary rather than trial-quantified, which for a bleeding mechanism is the right way around.
Longevity Lab Report
Lumbrokinase news. Graded when it happens.
The grade on this page stays free. The email carries the news on lumbrokinase: expert moves, dose changes, and what is working, in plain English every Thursday.
Changelog
Last updated 2026-10-23
- 2026-10-23|Graded from the human trial file in full. Lumbrokinase sits one step below nattokinase in this library because its file lacks even the large decisive trial that disciplined nattokinase's grade, and its safety reasoning borrows the fibrinolytic class caution that the nattokinase record established.
- 2026-10-23|Not listed under any goal beyond this record's category placement: no graded outcome finding exists to map.
The week's longevity and biohacking news.
This grade for Lumbrokinase rests on the record above. When a new result changes that record, the grade changes with it, and the Thursday email is where the change lands first: the week's longevity and biohacking news, in plain English, linked back to the reasoning on this page.
The week's longevity and biohacking news. Every story graded against the evidence. Free. Unsubscribe anytime.
Every grade follows a published rubric, and sponsors never change one. When the evidence moves a grade, Thursday is where you hear it first, before you renew a stack that stopped earning its cost.